DSM and Phynova reach global distribution agreement for blood glucose-support ingredient
Phynova has signed a global distribution and collaboration agreement for its Reducose ingredient with DSM.
Photo © stock.adobe,com/6okean
Phynova (Oxfordshire, UK) has signed a global distribution and collaboration agreement for its Reducose ingredient with DSM (Kaiseraugst, Switzerland). Reducose is a patented water extract of white mulberry leaves (Morus alba) that supports healthy blood glucose levels by reducing the absorption of sugars and other carbohydrate by up to 40%, says the company.
“We are delighted to work with DSM, the leading global health and nutrition ingredient specialist,” said Robert Miller, CEO of Phynova, in a press release. “Along with the distribution and sales of Reducose, we will collaborate closely with them on product development, clinical research, regulatory approvals, and marketing.”
“Phynova is a strategic partner for DSM to provide the right nutritional solutions to address the ever-growing health concerns linked to maintaining healthy blood glucose,” explained Ivo Lansbergen, VP global strategic marketing, DSM Human Nutrition and Health, in a press release. “The combined strengths of DSM and Phynova provide an excellent platform for addressing this major societal challenge.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
